In that study, a monoclonal antibody was selected that masks MICA and MICB α3 domain, the site of proteolytic shedding by metzincins, namely ADAMs, preventing loss of cell surface MICA and MICB by human cancer cells. This evidence concerns the gene MICB and cancer.